And then I guess, you know, especially when you talk about cost management right now, expense management and you have multiple ongoing studies and what have you I want to focus on manufacturing with regard to you know your ability to serve you know your larger studies right now and your additional initiatives versus you know do you have any immediate term or nearer term needs with regard to manufacturing capacity so right now I actually think that our current manufacturing capabilities will be fine for all four clinical trials, for both the autologous BCO1 and BCO2 and the allogeneic BCDA03 and BCDA04.

Mar 29, 2023 / receipt, needs a key / Joe Pangenis, other | earnings call 2023-03-29 | transcript 2d435624-0e5c-4c79-8876-d5cc460b8c30 | chars 19950-20559 | segment 19